<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002608</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-OTT-9401</org_study_id>
    <secondary_id>CDR0000063892</secondary_id>
    <secondary_id>NCI-V94-0566</secondary_id>
    <nct_id>NCT00002608</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors</brief_title>
  <official_title>Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different
      ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate
      the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the
      uptake of estrogen. Combining tamoxifen with chemotherapy may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving cisplatin and doxorubicin together
      with tamoxifen works in treating patients with solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in
           patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or
           adrenal cancer.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV
      over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment
      continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at
      least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial
      remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete
      remission.

      Patients are followed every 2 months for 1 year and then every 3 months for 2 years.

      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1994</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Pheochromocytoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid
             cancer, or adrenal cancer with clinical, radiological, or histologic evidence of
             incurability

          -  Patients with thyroid cancer must have failed radioactive iodine

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and under

        Performance status:

          -  ECOG 0-2

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm3

          -  Platelet count at least 140,000/mm3

        Hepatic:

          -  Bilirubin normal

        Renal:

          -  Creatinine less than 1.47 mg/dL

        Cardiovascular:

          -  Left ventricular ejection fraction at least 50% by MUGA scan

          -  No congestive heart failure

          -  No severe, uncontrolled hypertension

          -  No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG

        Other:

          -  No allergy to study medications

          -  No uncontrolled infection

          -  No active abuse of ethanol that would preclude treatment

          -  No other prior or concurrent malignancy

          -  Not pregnant

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No more than 1 prior chemotherapy regimen

          -  No prior anthracycline or cisplatin

          -  At least 3 weeks since other prior chemotherapy and recovered

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to more than 25% of bone marrow

          -  At least 3 weeks since other prior radiotherapy and recovered

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stan Z. Gertler, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Ottawa Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Gertler SZ, Yau J, Stewart DJ, et al.: Cisplatin, doxorubicin and tamoxifen (CAT) in the treatment of incurable soft tissue and endocrine malignancies-preliminary results. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A1427, 1996.</citation>
  </results_reference>
  <verification_date>May 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>childhood brain tumor</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>childhood liver cancer</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>stage IV adrenocortical carcinoma</keyword>
  <keyword>recurrent adrenocortical carcinoma</keyword>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>metastatic pheochromocytoma</keyword>
  <keyword>recurrent pheochromocytoma</keyword>
  <keyword>childhood soft tissue sarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

